Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers.

Abstract

T Cell Modulatory Peptide (TCMP-80), L-lysine-L-serine, is a synthetic dipeptide structurally related to a selected amino acid sequence in human immunoglobulin G. Based on in vitro and preclinical in vivo testing, TCMP-80 has immunomodulatory properties. This report describes the first administration of TCMP-80 to man in a randomized, double-blind, placebo-controlled, single rising-dose tolerability trial. Healthy male volunteers received TCMP-80 or placebo as a 10-minute intravenous infusion. At weekly intervals, two of four subjects were given TCMP-80; the remaining two received placebo. Each subject could receive only one dose during the study. Dosing started at 0.01 mg/kg and was increased to 0.03, 0.1, 0.3, 1, 3, 6.5, and 10 mg/kg. CBCs, blood chemistries, urinalyses, and lymphocyte subset populations were monitored predose and postdose on Days 1, 5, and 14. Three placebo and three TCMP-80 subjects reported adverse events. Adverse events reported after TCMP-80 administration were mild in nature (headache, dizziness, hematoma at injection site), appeared to be independent of dose, and resolved without medical intervention. No clinically significant alterations in vital signs, physical examination parameters, or clinical laboratory values were observed. Based on the results of this study, TCMP-80 is safe and well-tolerated within the dose range studied when administered as single intravenous infusions. Additionally, this study design represents an approach to assess the safety of an investigational immunomodulatory drug.

• Authors: M A Eldon, R A Smith, P T Leese, A E Daigle, D V Katz, S P Richieri
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 30 Issue 4 Pg. 352-7 (Apr 1990) ISSN: 0091-2700 [Print] England
• PMID: 2140370 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Dipeptides
• lysyl-serine

Topics

• Adult
• Dipeptides (administration & dosage, therapeutic use)
• Double-Blind Method
• Drug Administration Schedule
• Humans
• Injections, Intravenous
• Leukocyte Count
• Male
• Middle Aged
• Randomized Controlled Trials as Topic
• Risk Factors
• T-Lymphocytes, Helper-Inducer (drug effects)
• T-Lymphocytes, Regulatory (drug effects)
• Time Factors